Scleroderma is a systemic autoimmune disease where the immune system attacks healthy skin/tissue and causes it to harden. There are both lesser and more serious forms of the disease. The serious form of the disease affects the internal organs. It is a nasty disease from what I can see and currently there is no cure.
The article I linked is authored by a man that has a hypothesis that MST 188 May be a potential treatment option for this disease. It is just that, his hypothesis and it appears that he reached out to Mast and they found his article of interest. That's really it right now. I thought the article made sense when I found it and since it mentioned our lead drug candidate I linked it here.
The author seems to be very passionate about finding treatment options for this rare disease. This is not a Seeking Alpha type of article meant to sway investors one way or another. It is an article he wrote for a Scleroderma focused website as information for those associated in some way with this disease, and I stumbled upon it on a weekend evening surfing the net.
That's about all I have for you on this. I hope that helps. RR
News 
Market Data 
Discover 
